{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:14:40Z","timestamp":1788250480176,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11060-026-05717-x","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:32:13Z","timestamp":1784820733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Salvage therapies for recurrent grade 4 IDH-wildtype glioma: a BRAIN Registry analysis of real-world treatment patterns"],"prefix":"10.1007","volume":"179","author":[{"given":"Emma","family":"Sanderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Drummond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwan","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Freilich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ahern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Harrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Jennens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lynam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisi Elizabeth","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Gately","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"Issue Supplemen","key":"5717_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaf194","volume":"27","author":"M Price","year":"2025","unstructured":"Price M, Pittman Ballard CA, Benedetti JR, Kruchko C, Barnholtz-Sloan JS, Ostrom QT (2025) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2018\u20132022. Neuro Oncol 27(Issue Supplement 4):iv1\u2013iv66. https:\/\/doi.org\/10.1093\/neuonc\/noaf194","journal-title":"Neuro Oncol"},{"key":"5717_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K et al (2005) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"issue":"17","key":"5717_CR3","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.3390\/cancers15174279","volume":"15","author":"MA Vaz-Salgado","year":"2023","unstructured":"Vaz-Salgado MA, Villamayor M, Albarr\u00e1n V, Al\u00eda V, Sotoca P, Chamorro J et al (2023) Recurrent Glioblastoma: A Review of the Treatment Options. Cancers (Basel) 15(17):4279. https:\/\/doi.org\/10.3390\/cancers15174279","journal-title":"Cancers (Basel)"},{"issue":"4","key":"5717_CR4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/caac.21613","volume":"70","author":"AC Tan","year":"2020","unstructured":"Tan AC, Ashley DM, L\u00f3pez GY, Malinzak M, Friedman HS, Khasraw M (2020) Management of glioblastoma: State of the art and future directions. CA Cancer J Clin 70(4):299\u2013312. https:\/\/doi.org\/10.3322\/caac.21613","journal-title":"CA Cancer J Clin"},{"key":"5717_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:170\u2013186. https:\/\/doi.org\/10.1038\/s41571-020-00447-z","journal-title":"Nat Rev Clin Oncol"},{"key":"5717_CR6","unstructured":"National Comprehensive Cancer Network (2025) Central nervous system cancers. version 2.2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cns.pdf. Accessed 5 Nov 2025"},{"issue":"8","key":"5717_CR7","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen PY, Weller M, Quant Lee E, Alexander BM, Barnholtz-Sloan JS, Barthel FP et al (2020) Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol 22(8):1073\u20131113. https:\/\/doi.org\/10.1093\/neuonc\/noaa106","journal-title":"Neuro Oncol"},{"issue":"1","key":"5717_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/neuonc\/nov145","volume":"18","author":"F Ringel","year":"2016","unstructured":"Ringel F, Pape H, Sabel M, Krex D, Christoph Bock H, Misch M et al (2016) Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. Neuro Oncol 18(1):96\u2013104. https:\/\/doi.org\/10.1093\/neuonc\/nov145","journal-title":"Neuro Oncol"},{"issue":"9","key":"5717_CR9","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-14-2737","volume":"21","author":"M Weller","year":"2015","unstructured":"Weller M, Tabatabai G, K\u00e4stner B, Felsberg J, Steinbach JP, Wick A et al (2015) MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clin Cancer Res 21(9):2057\u20132064. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2737","journal-title":"Clin Cancer Res"},{"issue":"5","key":"5717_CR10","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1227\/neu.0000000000001338","volume":"79","author":"PA Tully","year":"2016","unstructured":"Tully PA, Gogos AJ, Love C, Liew D, Drummond KJ, Morokoff AP (2016) Reoperation for Recurrent Glioblastoma and Its Association with Survival Benefit. Neurosurgery 79(5):678\u2013689. https:\/\/doi.org\/10.1227\/neu.0000000000001338","journal-title":"Neurosurgery"},{"key":"5717_CR11","doi-asserted-by":"publisher","first-page":"110696","DOI":"10.1016\/j.radonc.2024.110696","volume":"204","author":"N Andratschke","year":"2025","unstructured":"Andratschke N, Heusel A, Albert NL, Alongi F, Baumert BG, Belka C et al (2025) ESTRO\/EANO recommendation on reirradiation for glioblastoma. Radiother Oncol 204:110696. https:\/\/doi.org\/10.1016\/j.radonc.2024.110696","journal-title":"Radiother Oncol"},{"key":"5717_CR12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11060-017-2564-z","volume":"135","author":"ME van Linde","year":"2017","unstructured":"van Linde ME, Brahm CG, de Witt Hamer PC, Reijneveld JC, Bruynzeel AME, Vandertop WP et al (2017) Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. J Neurooncol 135:183\u2013192. https:\/\/doi.org\/10.1007\/s11060-017-2564-z","journal-title":"J Neurooncol"},{"key":"5717_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s11060-024-04808-x","volume":"170","author":"A Hainfellner","year":"2024","unstructured":"Hainfellner A, Borkovec M, Seebrecht L, Neuhauser M, Roetzer-Pejrimovsky T, Gruetter L et al (2024) Glioblastoma in the real\u2013world setting: patterns of care and outcome in the Austrian population. J Neurooncol 170:407\u2013418. https:\/\/doi.org\/10.1007\/s11060-024-04808-x","journal-title":"J Neurooncol"},{"key":"5717_CR14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1227\/neu.0000000000002903","volume":"95","author":"D Kim","year":"2024","unstructured":"Kim D, Lee JH, Kim N, Lim DH, Song JH, Suh CO et al (2024) Optimizing Recurrent Glioblastoma Salvage Treatment: A Multicenter Study Integrating Genetic Biomarkers From the Korean Radiation Oncology Group (21\u2009\u2013\u200902). Neurosurgery 95:584\u2013595. https:\/\/doi.org\/10.1227\/neu.0000000000002903","journal-title":"Neurosurgery"},{"issue":"9","key":"5717_CR15","doi-asserted-by":"publisher","first-page":"5533","DOI":"10.1007\/s10072-022-06172-y","volume":"43","author":"V Villani","year":"2022","unstructured":"Villani V, Prosperini L, Lecce M, Tanzilli A, Farnetti A, Benincasa D et al (2022) Recurrent glioblastoma: which treatment? A real\u2013world study from the Neuro\u2013oncology Unit Regina Elena National Cancer Institute. Neurol Sci 43(9):5533\u20135541. https:\/\/doi.org\/10.1007\/s10072-022-06172-y","journal-title":"Neurol Sci"},{"issue":"1","key":"5717_CR16","doi-asserted-by":"publisher","first-page":"vdaf009","DOI":"10.1093\/noajnl\/vdaf009","volume":"7","author":"S Paus","year":"2025","unstructured":"Paus S, Hoffmann J, Roeper J, Griesinger F (2025) Real-world analysis of treatment patterns and survival outcome of glioblastoma patients in a German single-center study: Can survival rates of randomized controlled trials be achieved? Neurooncol Adv 7(1):vdaf009. https:\/\/doi.org\/10.1093\/noajnl\/vdaf009","journal-title":"Neurooncol Adv"},{"key":"5717_CR17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1186\/s12885-022-09700-3","volume":"22","author":"L Gately","year":"2022","unstructured":"Gately L, Drummond K, Rosenthal M, Harrup R, Dowling A, Gogos A et al (2022) Beyond standard data collection \u2013 the promise and potential of (Brain tumour Registry Australia INnovation and translation registry). BMC Cancer 22:604. https:\/\/doi.org\/10.1186\/s12885-022-09700-3","journal-title":"BMC Cancer"},{"issue":"11","key":"5717_CR18","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/neuonc\/nov104","volume":"17","author":"KM Field","year":"2015","unstructured":"Field KM, Simes J, Nowak AK, Cher L, Wheeler H, Hovey EJ et al (2015) Randomised phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro Oncol 17(11):1504\u20131513. https:\/\/doi.org\/10.1093\/neuonc\/nov104","journal-title":"Neuro Oncol"},{"issue":"9","key":"5717_CR19","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1093\/neuonc\/noad074","volume":"25","author":"P Karschnia","year":"2023","unstructured":"Karschnia P, Dono A, Young JS, Juenger ST, Teske N, H\u00e4ni L et al (2023) Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group. Neuro Oncol 25(9):1672\u20131685. https:\/\/doi.org\/10.1093\/neuonc\/noad074","journal-title":"Neuro Oncol"},{"key":"5717_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jocn.2018.04.004","volume":"53","author":"RA Sastry","year":"2018","unstructured":"Sastry RA, Shankar GM, Gerstner ER, Curry WT (2018) The impact of surgery on survival after progression of glioblastoma: A retrospective cohort analysis of a contemporary patient population. J Clin Neurosci 53:41\u201347. https:\/\/doi.org\/10.1016\/j.jocn.2018.04.004","journal-title":"J Clin Neurosci"},{"key":"5717_CR21","unstructured":"Surgery for Recurrent Glioblastoma (RESURGE) Clinicaltrials.gov identifier: NCT02394626. Updated 4 Feb 2025. https:\/\/clinicaltrials.gov\/study\/NCT02394626. Accessed 5 Nov 2025"},{"issue":"28","key":"5717_CR22","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733\u20134740. https:\/\/doi.org\/10.1200\/JCO.2008.19.8721","journal-title":"J Clin Oncol"},{"key":"5717_CR23","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","volume":"27","author":"TN Kriesl","year":"2008","unstructured":"Kriesl TN, Kim L, Moore K, Duic P, Royce C, Stroud I et al (2008) Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma. J Clin Oncol 27:740\u2013745. https:\/\/doi.org\/10.1200\/JCO.2008.16.3055","journal-title":"J Clin Oncol"},{"key":"5717_CR24","unstructured":"Australian Government Department of Health (2010) Australian public assessment report for bevacizumab. Therapeutics Goods Administration. https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-bevacizumab-091214-01.pdf. Accessed 5 Nov 2025"},{"issue":"20","key":"5717_CR25","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I et al (2017) Lomustine and Bevacizumab in Progressive Glioblastoma. N Eng J Med 377(20):1954\u20131963. https:\/\/doi.org\/10.1056\/NEJMoa1707358","journal-title":"N Eng J Med"},{"issue":"9","key":"5717_CR26","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","volume":"15","author":"W Taal","year":"2014","unstructured":"Taal W, Oosterkamp HM, Walenkamp AME, Dubbink HJ, Beerepoot LV, Hanse MCJ et al (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15(9):943\u2013953. https:\/\/doi.org\/10.1016\/S1470-2045(14)70314-6","journal-title":"Lancet Oncol"},{"issue":"1","key":"5717_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","volume":"20","author":"G Lombardi","year":"2018","unstructured":"Lombardi G, De Salvo GL, Brandes AA, Eoli M, Rud\u00e0 R, Faedi M et al (2018) Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 20(1):110\u2013119. https:\/\/doi.org\/10.1016\/S1470-2045(18)30675-2","journal-title":"Lancet Oncol"},{"key":"5717_CR28","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s12885-023-11043-6","volume":"23","author":"M Fu","year":"2023","unstructured":"Fu M, Zhou Z, Huang X, Chen Z, Zhang L, Zhang J et al (2023) Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map. BMC Cancer 23:544. https:\/\/doi.org\/10.1186\/s12885-023-11043-6","journal-title":"BMC Cancer"},{"key":"5717_CR29","doi-asserted-by":"publisher","first-page":"102029","DOI":"10.1016\/j.ctrv.2020.102029","volume":"87","author":"M Weller","year":"2020","unstructured":"Weller M, Le Rhun E (2020) How did lomustine become standard of care in recurrent glioblastoma? Cancer Treat Rev 87:102029. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102029","journal-title":"Cancer Treat Rev"},{"issue":"26","key":"5717_CR30","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1200\/jco.2012.47.2464","volume":"31","author":"TT Batchelor","year":"2013","unstructured":"Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A et al (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31(26):3212\u20133218. https:\/\/doi.org\/10.1200\/jco.2012.47.2464","journal-title":"J Clin Oncol"},{"key":"5717_CR31","unstructured":"Australian Government department of health, disability and ageing (2019) Recommendations made by the PBAC \u2013 May 2019. Pharmaceutical benefit advisory committee outcomes. https:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/pbac-outcomes\/recommendations-made-by-pbac-may-2019. Accessed 5 Nov 2025"},{"key":"5717_CR32","unstructured":"Australian government department of health, disability and ageing about the PBS. The Pharmaceutical Benefits Scheme. https:\/\/www.pbs.gov.au\/info\/about-the-pbsWhat_is_the_PBS. Accessed 5 Nov 2025"},{"key":"5717_CR33","doi-asserted-by":"publisher","unstructured":"Wen PY, Berry DA, Buxton MB, Colman H, de Groot J, Lim M et al (2026) Evaluation of regorafenib in newly diagnosed and recurrent glioblastoma: GBM AGILE Phase II\/III Bayesian Randomized Platform Trial. J Clin Oncol 0. https:\/\/doi.org\/10.1200\/JCO-25-01137","DOI":"10.1200\/JCO-25-01137"},{"issue":"12","key":"5717_CR34","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.3174\/ajnr.A4898","volume":"37","author":"HS Nguyen","year":"2016","unstructured":"Nguyen HS, Milbach N, Hurrell SL, Cochran E, Connelly J, Bovi JA et al (2016) Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma. AJNR Am J Neuroradiol 37(12):2201\u20132208. https:\/\/doi.org\/10.3174\/ajnr.A4898","journal-title":"AJNR Am J Neuroradiol"},{"issue":"2","key":"5717_CR35","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","volume":"14","author":"BM Ellingson","year":"2017","unstructured":"Ellingson BM, Wen PY, Cloughesy TF (2017) Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics 14(2):307\u2013320. https:\/\/doi.org\/10.1007\/s13311-016-0507-6","journal-title":"Neurotherapeutics"},{"key":"5717_CR36","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen PY, van den Bent M, Youssef G, Cloughsey TF, Ellingson BM, Weller M, Galanis E et al (2023) RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol 41:5187\u20135199. https:\/\/doi.org\/10.1200\/JCO.23.01059","journal-title":"J Clin Oncol"},{"issue":"1","key":"5717_CR37","doi-asserted-by":"publisher","first-page":"vdac027","DOI":"10.1093\/noajnl\/vdac027","volume":"4","author":"R Fu","year":"2022","unstructured":"Fu R, Szidonya L, Barajas RF Jr, Ambady P, Varallyay C, Neuwelt EA (2022) Diagnostic performance of DSC perfusion MRI to distinguish tumor progression and treatment-related changes: a systematic review and meta-analysis. Neurooncol Adv 4(1):vdac027. https:\/\/doi.org\/10.1093\/noajnl\/vdac027","journal-title":"Neurooncol Adv"},{"issue":"6","key":"5717_CR38","doi-asserted-by":"publisher","first-page":"e2010651","DOI":"10.1001\/jamanetworkopen.2020.10651","volume":"3","author":"JM Unger","year":"2020","unstructured":"Unger JM, Blanke CD, LeBlanc M, Hershman DL (2020) Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials. JAMA 3(6):e2010651. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.10651","journal-title":"JAMA"},{"key":"5717_CR39","unstructured":"Cancer A (2020) COVID-19 Recovery: implications for cancer care. Cancer Australia. https:\/\/www.canceraustralia.gov.au\/sites\/default\/files\/migrated-files\/publications\/covid-19-recovery-implications-cancer-care\/pdf\/covid19-recovery-implications-cancer-care_1.pdf. Accessed 5 Nov 2025"},{"issue":"1","key":"5717_CR40","doi-asserted-by":"publisher","first-page":"vdae039","DOI":"10.1093\/noajnl\/vdae039","volume":"6","author":"U Sener","year":"2024","unstructured":"Sener U, Islam M, Webb M, Kizibash SH (2024) Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design. Neurooncol Adv 6(1):vdae039. https:\/\/doi.org\/10.1093\/noajnl\/vdae039","journal-title":"Neurooncol Adv"},{"key":"5717_CR41","unstructured":"Omico (2025) Omico\u2019s impact report: from momentum to mainstream. Omico. https:\/\/www.omico.com.au\/wp-content\/uploads\/2025\/11\/Omico-Impact-REPORT_Online-pdf-version_2025.pdf. Accessed 29 Apr 2026"},{"issue":"1","key":"5717_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/neuonc\/noac226","volume":"25","author":"J Ricardo McFaline-Figueroa","year":"2023","unstructured":"Ricardo McFaline-Figueroa J, Wen PY (2023) Negative trials over and over again: How can we do better? Neuro Oncol 25(1):1\u20133. https:\/\/doi.org\/10.1093\/neuonc\/noac226","journal-title":"Neuro Oncol"},{"issue":"4","key":"5717_CR43","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1158\/1078-0432.CCR-21-2750","volume":"24","author":"SJ Bagley","year":"2022","unstructured":"Bagley SJ, Kothari S, Rahman R, Lee EQ, Dunn GP, Galanis E (2022) Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. Clin Cancer Res 24(4):594\u2013602. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2750","journal-title":"Clin Cancer Res"},{"key":"5717_CR44","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/s1470-2045(21)00488-5","volume":"22","author":"R Rahman","year":"2021","unstructured":"Rahman R, Ventz S, McDunn J, Louv B, Reyes-Rivera I, Polley MYC (2021) Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncol 22:e456\u2013e465. https:\/\/doi.org\/10.1016\/s1470-2045(21)00488-5","journal-title":"Lancet Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05717-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05717-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05717-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:27:18Z","timestamp":1788247638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05717-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5717"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05717-x","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The BRAIN registry (Brain Registry Australia: INnovation and translation) has ethics approval by the Melbourne Health Ethics Committee (Date: 2018\/Ref No: HREC\/44314\/MH-2018) and is registered on the Australia New Zealand Clinical Trials Registry (registration number: ACTRN12618001959268). A waiver of consent model was approved by the Human Ethics and Research Committee.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"13"}}